This database contains 67 studies, archived under the term: "Journal Of Alzheimer's Disease: JAD"
Click here to filter this large number of results.
Comparison of two analytical platforms for the clinical qualification of Alzheimer’s disease biomarkers in pathologically-confirmed dementia
Le Bastard, Nathalie,
Coart, Els,
Vanderstichele, Hugo,
Vanmechelen, Eugeen,
Martin, Jean-Jacques,
Engelborghs, Sebastiaan
Combined analysis of the Alzheimer’s disease (AD) biomarkers amyloid-β(1-42) (Aβ(1-42)), total tau (T-tau), and hyperphosphorylated tau (P-tau(181P)) in cerebrospinal fluid (CSF) reduces the uncertainty associated with clinical dementia diagnosis. The present study evaluated the diagnostic accuracy of the CSF biomarker concentrations obtained with a multi-analyte Luminex assay (INNO-BIA AlzBio3) in comparison to single-analyte ELISA tests […]
Memantine is associated with longer survival than donepezil in a Veterans Affairs prescription database, 1997 to 2008
Lazzeroni, Laura C.,
Halbauer, Joshua D.,
Ashford, J. Wesson,
Noda, Art,
Hernandez, Beatriz,
Azor, Virgina,
Hozack, Nikki,
Hasson, Noelle,
Henderson, Victor W.,
Yesavage, Jerome A.,
Tinklenberg, Jared R.
Alzheimer’s disease (AD) shortens life-expectancy, but the effects of pharmacological treatments for this disorder on mortality have not been studied. We compared two commonly prescribed medications, donepezil and memantine, with respect to the length of survival of veterans presumed to have AD. The Computerized Medical Records System at the Veterans Affairs Palo Alto Health Care […]
Long-term statin therapy is associated with better episodic memory in aged familial hypercholesterolemia patients in comparison with population controls
Hyttinen, Laura,
TuulioHenriksson, Annamari,
Vuorio, Alpo F.,
Kuosmanen, Noora,
Härkänen, Tommi,
Koskinen, Seppo,
Strandberg, Timo E.
The cognitive status of aged familial hypercholesterolemia (FH) patients treated with long-term statin therapy was compared with that of population controls. A comprehensive cohort of 43 elderly (age > or = 65 years) patients all with the same FH North Karelia mutation living in North Karelia (eastern Finland) was identified, 37 of whom (aged 65 […]
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study
Gareri, Pietro,
Putignano, Daria,
Castagna, Alberto,
Cotroneo, Antonino Maria,
De Palo, Grazia,
Fabbo, Andrea,
Forgione, Luigi,
Giacummo, Attilio,
Lacava, Roberto,
Marino, Saverio,
Simone, Maurizio,
Zurlo, Amedeo,
Putignano, Salvatore
Background: Combined therapy of memantine and acetylcholinesterase inhibitors (AChEIs) in patients with Alzheimer’s disease (AD) may be associated with higher benefits than either monotherapy.; Objective: This retrospective multicentric study conducted in seven Italian Ambulatory Centers for Dementia assessed the efficacy and safety of memantine 20 mg/day administered for 6 months in addition to an AChEI […]
Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n – 3 fatty acid supplementation in patients with Alzheimer’s disease: the OmegAD study
Faxén-Irving, Gerd,
Freund-Levi, Yvonne,
Eriksdotter-Jönhagen, Maria,
Basun, Hans,
Hjorth, Erik,
Palmblad, Jan,
Vedin, Inger,
Cederholm, Tommy,
Wahlund, Lars-Olof
Transthyretin (TTR) binds amyloid-β (Aβ) and may reduce brain Aβ, a pathological feature in Alzheimer’s disease (AD). N – 3 fatty acids (FA), docosahexaenoic (DHA), and eicosapentaenoic acid (EPA) may increase TTR transcription in rat hippocampus. We studied effects of n – 3 FA supplementation on TTR-levels in patients with AD. Outpatients were randomized to […]
Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: a pilot study
del Ser, Teodoro,
Steinwachs, Klaus C.,
Gertz, Hermann J.,
Andrés, María V.,
Gómez-Carrillo, Belén,
Medina, Miguel,
Vericat, Joan A.,
Redondo, Pilar,
Fleet, David,
Leon, Teresa
This pilot, double-blind, placebo-controlled, randomized, escalating dose trial explored the safety and efficacy of tideglusib, an inhibitor of glycogen synthase kinase-3, in Alzheimer’s disease (AD) patients. Thirty mild-moderate AD patients on cholinesterase inhibitor treatment were administered escalating doses (400, 600, 800, 1,000 mg) of tideglusib or placebo (ratio 2 : 1) for 4, 4, 6, […]
Silicon-rich mineral water as a non-invasive test of the ‘aluminum hypothesis’ in Alzheimer’s disease
Davenward, Samantha,
Bentham, Peter,
Wright, Jan,
Crome, Peter,
Job, Deborah,
Polwart, Anthony,
Exley, Christopher
There has been a plausible link between human exposure to aluminum and Alzheimer’s disease for several decades. We contend that the only direct and ethically acceptable experimental test of the ‘aluminum hypothesis’, which would provide unequivocal data specific to the link, is to test the null hypothesis that a reduction in the body burden of […]